Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients

Summary

This is a randomized, double-blind, placebo-controlled, multicentre, parallel-group study to assess the cognitive effects of lurasidone in bipolar I and II patients (manic depression) who are in remission from an episode. Participants who show cognitive impairment at the screening visit will be enrolled into the study and randomized at the baseline visit to receive either lurasidone or placebo adjunctive therapy in a 1:1 ratio for 6 weeks.

Timeline

Start

2017-05-08

Primary completion

2024-12-31

Completion

2024-12-31

Drugs

Indications